Chad Gassert Sells 20,000 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Chad Gassert sold 20,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $67.25, for a total transaction of $1,345,000.00. Following the sale, the senior vice president now directly owns 253,226 shares of the company’s stock, valued at approximately $17,029,448.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

ANI Pharmaceuticals Stock Up 0.8 %

Shares of NASDAQ:ANIP opened at $67.24 on Thursday. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. ANI Pharmaceuticals, Inc. has a 52-week low of $36.99 and a 52-week high of $70.81. The company has a 50 day moving average of $62.30 and a two-hundred day moving average of $58.00. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of 80.05 and a beta of 0.79.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. As a group, analysts forecast that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ANIP. China Universal Asset Management Co. Ltd. boosted its stake in shares of ANI Pharmaceuticals by 93.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 248 shares during the last quarter. BluePath Capital Management LLC bought a new position in ANI Pharmaceuticals during the third quarter worth $34,000. C M Bidwell & Associates Ltd. bought a new position in ANI Pharmaceuticals during the second quarter worth $35,000. Pacer Advisors Inc. bought a new position in ANI Pharmaceuticals during the fourth quarter worth $41,000. Finally, Point72 Asset Management L.P. lifted its stake in ANI Pharmaceuticals by 60.0% during the second quarter. Point72 Asset Management L.P. now owns 776 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 291 shares during the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ANIP. Capital One Financial began coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 15th. They set an “overweight” rating and a $80.00 target price for the company. HC Wainwright increased their target price on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. Truist Financial increased their target price on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, Guggenheim increased their target price on shares of ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $80.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.